Personalized medicine for kidney disease: can genes predict who will respond?
NCT ID NCT07416942
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to find genetic and protein markers that can predict whether patients with membranous nephropathy, a kidney disease, will respond to the drug rituximab. Researchers will analyze stored blood and tissue samples from 120 patients and healthy volunteers. The goal is to develop a personalized approach to treatment, avoiding ineffective therapies and their side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors choose the right treatment for membranous nephropathy patients, improving outcomes and reducing side effects.
What could go wrong
This is an observational study on stored samples, not a treatment trial. The findings may not lead to immediate clinical changes or may not be confirmed in future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
Ranica, BG, 24020, Italy
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••